公开(公告)号：US12121539B2

公开(公告)日：2024-10-22

申请号：US15759046

申请日：2016-09-10

申请人： BIOSCEPTRE (AUST) PTY LTD

发明人： Justin Taylor Coombs ,  Simon Charles Barry ,  Timothy John Sadlon

IPC分类号： A61K35/17 ,  C07K14/705 ,  C07K14/715 ,  C07K14/725 ,  C07K14/735 ,  C07K16/28 ,  C12N5/0786 ,  C07K19/00

CPC分类号： A61K35/17 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70535 ,  C07K14/70578 ,  C07K14/715 ,  C07K16/28 ,  C12N5/0645 ,  C07K19/00 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/30 ,  C07K2319/33 ,  C07K2319/60

摘要： The present invention relates to chimeric antigen receptors (CARs) directed to cells expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor. Further provided are methods of targeting neoplastic cells and tumours expressing a dysfunctional or non-functional P2X purinoceptor 7 receptor and methods of treating and preventing cancer is a subject.

公开(公告)号：US12109238B2

公开(公告)日：2024-10-08

申请号：US17812264

申请日：2022-07-13

申请人： ImmunityBio, Inc.

发明人： Laurent H. Boissel ,  Hans G. Klingemann

IPC分类号： A61K35/17 ,  A61K35/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

CPC分类号： A61K35/17 ,  A61K35/28 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/109 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

摘要： Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcεRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

公开(公告)号：US20240329033A1

公开(公告)日：2024-10-03

申请号：US18515636

申请日：2023-11-21

申请人： Temple University-Of The Commonwealth System of Higher Education

发明人： Jay Rappaport ,  Sarah Vakili

IPC分类号： G01N33/50 ,  C07K14/705 ,  C07K14/73 ,  C07K14/735 ,  C12N5/0786

CPC分类号： G01N33/5047 ,  C07K14/70514 ,  C07K14/70535 ,  C07K14/70596 ,  C12N5/0645 ,  C12N2501/052 ,  C12N2501/22 ,  C12N2501/24 ,  C12N2501/25 ,  C12N2501/30 ,  C12N2501/39 ,  C12N2501/999

摘要： The invention provides monocytes expressing CD16 and CD163 and experimental system for drug screening or evaluating drug candidates where the modulation of CD16 and CD163 is desired.

公开(公告)号：US20240307540A1

公开(公告)日：2024-09-19

申请号：US18575734

申请日：2022-07-01

申请人： Fate Therapeutics, Inc.

发明人： Bahram VALAMEHR ,  Ryan BJORDAHL ,  Jode GOODRIDGE ,  Alan WILLIAMS ,  Rina MBOFUNG

IPC分类号： A61K39/00 ,  C07K14/735 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/11 ,  C12N15/90

CPC分类号： A61K39/464412 ,  A61K39/4611 ,  A61K39/4631 ,  C07K14/70535 ,  C07K16/2896 ,  C12N5/0646 ,  C12N9/22 ,  C12N15/11 ,  C12N15/907 ,  A61K2239/39 ,  C07K2317/732 ,  C12N2310/20 ,  C12N2501/2315 ,  C12N2502/1164 ,  C12N2506/45

摘要： Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Embodiments of derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

公开(公告)号：US20240288430A1

公开(公告)日：2024-08-29

申请号：US18513107

申请日：2023-11-17

申请人： Genentech, Inc. ,  Foundation Medicine, Inc.

发明人： Craig Anthony CUMMINGS ,  Yan LI ,  Sarah Margaret SHAGAN ,  Erica Beth SCHLEIFMAN ,  David SHAMES ,  David FABRIZIO ,  Daniel LIEBER ,  Geoffrey Alan OTTO ,  Mark KENNEDY ,  Travis CLARK ,  Doron LIPSON ,  Jie HE ,  Shan ZHONG

IPC分类号： G01N33/574 ,  A61K39/00 ,  A61P35/00 ,  C07K14/735 ,  C07K16/28 ,  C12Q1/68 ,  C12Q1/6883 ,  G06F16/28 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70

CPC分类号： G01N33/574 ,  A61P35/00 ,  C07K14/70535 ,  C07K16/2827 ,  C07K16/2896 ,  C12Q1/68 ,  C12Q1/6883 ,  G01N33/57492 ,  G06F16/285 ,  G16H50/20 ,  G16H50/30 ,  G16H50/50 ,  G16H50/70 ,  A61K2039/505 ,  A61K2039/55 ,  C07K2317/24 ,  C12Q2600/156 ,  G01N2333/70532 ,  G01N2800/52

摘要： The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.

公开(公告)号：US20240239868A1

公开(公告)日：2024-07-18

申请号：US18407775

申请日：2024-01-09

申请人： Shiying Cai

发明人： Shiying Cai

IPC分类号： C07K14/735 ,  A61P37/06

CPC分类号： C07K14/70535 ,  A61P37/06 ,  A61K38/00 ,  C07K2319/70

摘要： Provided are polymeric immunoglobulin receptor mutants and uses thereof. Specifically, the present disclosure relates to a polymeric immunoglobulin receptor (pIgR) mutant for neutralizing an autoantibody against pIgR without interacting with a polymeric immunoglobulin, comprising an extracellular portion of wild-type pIgR with at least one amino acid mutation therein. The present disclosure also relates to an isolated nucleic acid encoding the amino acid sequence of the pIgR mutant, an expression vector comprising the isolated nucleic acid, a host cell comprising the expression vector, a pharmaceutical composition comprising the pIgR mutant and a method of treating an autoimmune disease.

公开(公告)号：US20240228636A1

公开(公告)日：2024-07-11

申请号：US18481797

申请日：2023-10-05

申请人： Cellectis ,  Allogene Therapeutics, Inc.

发明人： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC分类号： C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  G01N15/01 ,  G01N15/10 ,  G01N15/1031 ,  G01N15/14 ,  G01N15/149

CPC分类号： C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001176 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  G01N15/1031 ,  G01N15/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  G01N2015/016 ,  G01N2015/1006 ,  G01N2015/1028 ,  G01N15/149

摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US20240207315A1

公开(公告)日：2024-06-27

申请号：US18397019

申请日：2023-12-27

申请人： Gilboa Therapeutics LTD

发明人： Noam PILPEL ,  Peleg RIDER ,  Yaron CARMI ,  Shahar DOTAN ,  Diana RASOULOUNIRIANA ,  Hana SHPILT

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K14/735

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  C07K14/70535 ,  A61K2239/15 ,  A61K2239/21 ,  A61K2239/22

摘要： Chimeric receptors are provided. Accordingly, there is provided a chimeric receptor comprising an extracellular binding domain and a heterologous amino acid sequence capable of recruiting a co-receptor comprising an intracellular signaling domain, such that upon binding of the extracellular binding domain to its target the signaling is transmitted in a cell expressing the chimeric receptor and the co-receptor. Also provided are protein complexes comprising the receptors, cells expressing same and uses thereof.

公开(公告)号：US20240124550A1

公开(公告)日：2024-04-18

申请号：US18474781

申请日：2023-09-26

申请人： Regents of the University of Minnesota

发明人： Jianming Wu ,  Bruce Kenneth Walcheck ,  Robert Harrison Hullsiek ,  Yungfang Li ,  Hemant Kumar Mishra

IPC分类号： C07K14/735 ,  C07K16/30 ,  C12N5/0783

CPC分类号： C07K14/70535 ,  C07K16/30 ,  C12N5/0646 ,  C07K2317/24 ,  C07K2319/74

摘要： A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

公开(公告)号：US20240102992A1

公开(公告)日：2024-03-28

申请号：US18366822

申请日：2023-08-08

申请人： NIPPON ZENYAKU KOGYO CO., LTD.

发明人： Takuya MIZUNO ,  Masaya Igase ,  Yoshiho Takeda

IPC分类号： G01N33/50 ,  C07K14/705 ,  C07K14/735 ,  G01N33/58

CPC分类号： G01N33/5011 ,  C07K14/70535 ,  C07K14/70596 ,  G01N33/581 ,  C07K2319/00

摘要： A low-variation and highly reproducible method for measuring antibody-dependent cellular cytotoxicity activity of an antibody for a dog as the subject of administration is provided.
A method for measuring antibody-dependent cellular cytotoxicity activity comprising a step of causing an antibody and cells in which a canine CD16-canine Fcε receptor γ chain fusion protein is expressed in human-derived NK cells to act on canine tumor-derived cells or cells which express a canine tumor antigen and a step of detecting the cell death of the canine tumor-derived cells or the cells which express the canine tumor antigen. Also, the method for measuring antibody-dependent cellular cytotoxicity activity in which the human-derived NK cells are NK-92 cells.